Ahammune Biosciences

Ahammune Biosciences is a clinical-stage biotechnology company focused on developing innovative, cost-effective treatments for chronic, immune-mediated skin diseases. The company's proprietary immuno-dermatology discovery platform targets key cellular processes that influence skin health and immunity without causing generalized immunosuppression. Its lead drug candidate, AB1001, is a first-in-class, non-steroidal topical small molecule designed to arrest the progression of vitiligo and stimulate repigmentation by targeting critical immune-melanocyte pathways. Having successfully completed Phase 1 clinical trials, Ahammune is advancing AB1001 into Phase 2 development while expanding its pipeline of patented molecules for other dermatological and autoimmune conditions.